| Jessica Bigornia, | |
|
475 22nd Ave Rm 127, Honolulu, HI 96816-4400 | |
| () - | |
| Not Available |
| Full Name | Jessica Bigornia |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 475 22nd Ave Rm 127, Honolulu, Hawaii |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063060382 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Bigornia, 475 22nd Ave Rm 127, Honolulu, HI 96816-4400 Ph: () - | Jessica Bigornia, 475 22nd Ave Rm 127, Honolulu, HI 96816-4400 Ph: () - |
News Archive
EDP Biotech, a Knoxville-based company today briefed Tennessee state legislators on its revolutionary ColoMarker™ colon cancer test which potentially could save 50,000 lives and more than $12 billion in healthcare costs annually in the U.S. Legislators were also provided the opportunity to personally experience the ColoMarker™ test by enrolling in the control study group for EDP's latest research.
A drug with potential to prevent epilepsy caused by a genetic condition may also help prevent more common forms of epilepsy caused by brain injury, according to researchers at Washington University School of Medicine in St. Louis.
Strengthening Native American families will help improve their children's health—that's the premise behind a research study targeting 3-, 4- and 5-year-olds and their caregivers on the Pine Ridge Reservation in South Dakota.
Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.
Scientists at Dana-Farber Cancer Institute have isolated a previously unknown protein in muscles that spurs their growth and increased power following resistance exercise. They suggest that artificially raising the protein's levels might someday help prevent muscle loss caused by cancer, prolonged inactivity in hospital patients, and aging.
› Verified 3 days ago
Lauren Marie Eudoxie, M.SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 725 Kapiolani Blvd, Honolulu, HI 96813 Phone: 808-596-4650 | |
Jacquelyn Jarachovic, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1519 Queen Emma St, Honolulu, HI 96813 Phone: 808-587-4510 | |
Shauna Ainuu, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 710 Green St, Honolulu, HI 96813 Phone: 808-536-3764 | |
Maria Jordan, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 475 22nd Ave Rm 127, Honolulu, HI 96816 Phone: 808-733-4940 | |
Tina Thanh Huong Le, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 475 22nd Ave # 302, Honolulu, HI 96816 Phone: 808-305-9750 Fax: 808-733-9154 | |
Marissa Lyn Cheape, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 475 22nd Ave Rm 127, Honolulu, HI 96816 Phone: 808-627-7300 | |
Mrs. Christie Eiko Hoota Iraha, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 475 22nd Ave Rm 127, Honolulu, HI 96816 Phone: 808-282-2333 |